HCA Healthcare posted a stronger-than-expected Q3 with revenue of $19.849B and adjusted EPS of $7.22, topping estimates. The company raised its FY2026 guidance for both earnings and sales, signaling durable profitability despite policy headwinds. The upbeat results, along with higher target prices from multiple banks, may support near-term upside and a re-rating of the stock.
HCA reported a solid Q3 with revenue and EBITDA above estimates and adjusted earnings of $7.22 per share, driving a raised FY2026 guidance. However, uninsured volume created a roughly $400 million payer-mix drag, offset by gains in insured revenue per admission and cost improvements. The company cautioned on Medicaid payment tailwinds amid policy fluidity, suggesting near-term stock pressure despite durable fundamentals.
BMO Capital began covering HCA with an Outperform rating and a $495 price target, signaling confidence in the hospital operator's growth prospects. With HCA trading around $438, the target implies roughly 13% potential upside over the next year, possibly attracting funds and support for multiple expansion as analysts react.
HCA reported solid Q2 2026 results with revenue of $20.23B and adjusted EPS of $7.59, topping estimates. The company reaffirmed 2026 guidance for EPS of $28.70-$30.50 and sales of $77B-$79.5B, signaling steady demand. The print triggered modest stock strength and likely upward revisions to some analysts' targets.
On July 14, 2026, HCA disclosed a substantial downgrade to FY2026 guidance due to a weaker payer mix from rising uninsured visits, lowering EPS to $28.70–$30.50 and revenue to $77–$79.5B, with EBITDA of $15.4–$16.1B. The stock closed down 6.95% to $363.60. Later, The Portnoy Law Firm announced a securities-fraud investigation, potentially adding litigation risk to an already challenged outlook.
HCA Healthcare posted strong Q1 results with a 4.3% revenue increase, aligning with expectations. The company reaffirmed its full-year earnings guidance, indicating stability in its financial outlook, which likely contributed to the 2.2% rise in share price.